Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease (Q43499118)

24 November 2017

Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease (English)

1 reference

24 November 2017

1 reference

Catia S Pereira

1

1 reference

24 November 2017

Olga Azevedo

2

1 reference

24 November 2017

M Luz Maia

3

1 reference

24 November 2017

Ana F Dias

4

1 reference

24 November 2017

Clara Sa-Miranda

5

1 reference

24 November 2017

M Fatima Macedo

6

1 reference

24 November 2017

1 February 2013

1 reference

Molecular Genetics and Metabolism

24 November 2017

1 reference

24 November 2017

108

1 reference

24 November 2017

241-248

1 reference

24 November 2017

4

1 reference

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Raising the NKT cell family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Presumed guilty: natural killer T cell defects and human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Targeting natural killer cells and natural killer T cells in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Distinct functional lineages of human V(alpha)24 natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Lysosomal glycosphingolipid recognition by NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Glycolipid antigen processing for presentation by CD1d molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Leukocyte perturbation associated with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Common and uncommon pathogenic cascades in lysosomal storage diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

The cellular pathology of lysosomal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.01.018

10.1016/J.YMGME.2013.01.018

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference